The advent of high-throughput small-molecule and in silico screening approaches has made it possible to develop novel Cbl-b inhibitors that have reversed immunosuppression of the TME and promoted tumor-specific T cell activation and tumor regression. The gene discussed is CBLB; the disease is neoplasm.